Filter by Year All Years 2024 2023 2022 Clear Search Clear Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica to Advance the Discovery of Novel Drugs for Neurological DiseaseOctober 2, 2024 Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and OncologyNovember 13, 2023 Charles River Laboratories’ Industry Experts to Present Advanced Modalities at Neuroscience 2023November 9, 2023 Charles River and Related Sciences Enter Multi-Program Collaboration to Pursue AI-Enabled Drug Discovery Utilizing LogicaSeptember 14, 2023 Accessing artificial intelligence in pharmaceutical laboratoriesJuly 9, 2023 Using Smart Tools for Smart DevelopmentMay 2, 2023 The Next Generation of Drugs Will Be Enhanced by Machine LearningApril 4, 2023 Flagship company teams up with Charles River for AI drug discoveryMarch 1, 2023 How AI Is Driving Innovation And De-Risking R&DMarch 1, 2023 Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical NeedsFebruary 16, 2023 Flagship’s Pioneering Medicines to carve a new drug discovery path with Charles River’s AIFebruary 16, 2023 Integrating Experimental Data and Artificial Intelligence to Accelerate Drug DiscoveryDecember 7, 2022 {{ x.title }}{{ x.date }} Load More There are no articles to display.